{"id":2823,"date":"2020-09-24T05:30:00","date_gmt":"2020-09-24T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/"},"modified":"2020-09-24T05:30:00","modified_gmt":"2020-09-24T05:30:00","slug":"xvivo-perfusions-teckningsoptionsprogram-2020-2022","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/","title":{"rendered":"XVIVO Perfusions teckningsoptionsprogram 2020\/2022"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) den 31 mars 2020 beslutade att emittera h\u00f6gst 408 000 teckningsoptioner av serie 2020\/2022 till anst\u00e4llda i XVIVO och XVIVOs svenska dotterbolag. Anm\u00e4lningsperioden f\u00f6r teckning av teckningsoptioner l\u00f6pte ut den 23 september 2020 och totalt tecknades 374 000 tecknings\u00acoptioner.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Anst\u00e4llda som har tecknat teckningsoptionerna har betalat en optionspremie motsvarande marknads\u00adv\u00e4rdet ber\u00e4knat enligt Black &amp; Scholes optionsv\u00e4rderings\u00admodell. Varje teckningsoption ber\u00e4ttigar till teckning av en ny aktie i XVIVO under perioden 2 maj\u201331\u00a0maj 2022 till en teckningskurs om 205,88 kronor, motsvarande 150 procent av det volymv\u00e4gda medelv\u00e4rdet av de betalkurser f\u00f6r XVIVOs aktie som noterats p\u00e5 Nasdaq Stockholm f\u00f6r varje handelsdag under perioden 4 maj\u201315 maj 2020. Anm\u00e4lningsperioden f\u00f6r teckning av teckningsoptioner l\u00f6pte ut den 23 september 2020 och totalt tecknades 374 000 teckningsoptioner, varvid den sista teckningen skedde den 2 juni 2020.<br \/>\u00a0<br \/>Vid fullt utnyttjande av samtliga teckningsoptioner kommer XVIXOs aktiekapital att \u00f6ka med cirka 9\u00a0559 kronor, motsvarande en utsp\u00e4dningseffekt om cirka 1,4 procent av det totala antalet aktier och r\u00f6ster i XVIVO.<br \/>\u00a0<br \/>G\u00f6teborg 24 september 2020<br \/>XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Dag Andersson, VD, +46 31-788 21 50,\u00a0<a href=\"mailto:dag.andersson@xvivoperfusion.com\" target=\"_blank\" rel=\"nofollow noopener\">dag.andersson@xvivoperfusion.com<\/a><br \/>Christoffer Rosenblad, CFO, +46 73-519 21 59,\u00a0<a href=\"mailto:christoffer.rosenblad@xvivoperfusion.com\" target=\"_blank\" rel=\"nofollow noopener\">christoffer.rosenblad@xvivoperfusion.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr\/>\n<p>XVIVO Perfusion AB \u00e4r ett medicinteknikbolag som utvecklar l\u00f6sningar och system f\u00f6r att bed\u00f6ma och bevara organ utanf\u00f6r kroppen, och f\u00f6r att selektera anv\u00e4ndbara organ och h\u00e5lla dem i optimal kondition i v\u00e4ntan p\u00e5 transplantation. XVIVO Perfusion AB har sitt huvudkontor i G\u00f6teborg och ytterligare kontor finns i Lund och i Denver, USA. XVIVO-aktien \u00e4r noterad p\u00e5 Nasdaq Stockholm och handlas under symbolen XVIVO. <br \/>Mer information finns att l\u00e4sa p\u00e5 hemsidan <a href=\"http:\/\/www.xvivoperfusion.com.\" target=\"_blank\" rel=\"nofollow noopener\">www.xvivoperfusion.com.<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-pdf\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/ce3a1e4a-f02c-4580-a301-3e9b52b2568c\/xvivo-perfusions-teckningsoptionsprogram-2020-2022.pdf\" target=\"_blank\" rel=\"nofollow noopener\">XVIVO Perfusions teckningsoptionsprogram 2020\/2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) den 31 mars 2020 beslutade att emittera h\u00f6gst 408 000 teckningsoptioner av serie&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2823","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO Perfusions teckningsoptionsprogram 2020\/2022 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusions teckningsoptionsprogram 2020\/2022 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) den 31 mars 2020 beslutade att emittera h\u00f6gst 408 000 teckningsoptioner av serie...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\\\/\",\"name\":\"XVIVO Perfusions teckningsoptionsprogram 2020\\\/2022 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2020-09-24T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusions teckningsoptionsprogram 2020\\\/2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusions teckningsoptionsprogram 2020\/2022 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusions teckningsoptionsprogram 2020\/2022 - XVIVO","og_description":"\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) den 31 mars 2020 beslutade att emittera h\u00f6gst 408 000 teckningsoptioner av serie...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/","name":"XVIVO Perfusions teckningsoptionsprogram 2020\/2022 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2020-09-24T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-teckningsoptionsprogram-2020-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusions teckningsoptionsprogram 2020\/2022"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}